FLX475   Click here for help

GtoPdb Ligand ID: 12153

Synonyms: example 43 [WO2018022992A1] | FLX-475
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: FLX475 is an orally bioavailable CCR4 antagonist that was developed by RAPT Therapeutics, and is one of the structures claimed in patent WO2018022992A1 [1]. Antagonising CCR4 is proposed to activate the immune response against Epstein-Barr Virus (EBV)-positive tumours [2]. FLX475's chemical structure was revealed during the first disclosures session at the 2022 ACS meeting in Chicago.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 70.31
Molecular weight 542.16
XLogP 5.59
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OCCN1CCC[C@@H](C1)C1CN(C1)c1cnc2c(n1)n(nc2C(F)(F)F)[C@@H](c1ccc(cc1Cl)Cl)C
Isomeric SMILES C[C@H](c1c(cc(cc1)Cl)Cl)n1c2nc(cnc2c(n1)C(F)(F)F)N1CC(C1)[C@H]1CCCN(C1)CCO
InChI InChI=1S/C24H27Cl2F3N6O/c1-14(18-5-4-17(25)9-19(18)26)35-23-21(22(32-35)24(27,28)29)30-10-20(31-23)34-12-16(13-34)15-3-2-6-33(11-15)7-8-36/h4-5,9-10,14-16,36H,2-3,6-8,11-13H2,1H3/t14-,15+/m1/s1
InChI Key AKSVALRPYDVQBS-CABCVRRESA-N
No information available.
Summary of Clinical Use Click here for help
FLX475 has been advanced to clinical studies to determine its efficacy against advanced tumours, either as a monotherapy, or in combination with other immuno-oncology agents.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04894994 FLX475 in Combination With Ipilimumab in Advanced Melanoma Phase 2 Interventional RAPT Therapeutics, Inc.
NCT04768686 FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer Phase 2 Interventional Hanmi Pharmaceutical Company Limited
NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Phase 1/Phase 2 Interventional RAPT Therapeutics, Inc.